n.a. (BPAX)

55.05
0.69 1.24
NASDAQ
Prev Close 55.74
Open 56.64
Day Low/High 54.22 / 56.64
52 Wk Low/High 12.79 / 56.99
Volume 182.41K
Exchange NASDAQ
P/E Ratio N/A
Div & Yield N.A. (N.A)
3 Small-Cap Stocks on Insiders' Radar

3 Small-Cap Stocks on Insiders' Radar

Here are three stocks in which corporate insiders have been accumulating shares recently.

This Price Leap Is Undeniable

This Price Leap Is Undeniable

A new long-side idea is AIS, which shows a strong move with a high level of interest.

The Biotech Stock 13F Review: What Hedge Funds Were Buying and Selling

The Biotech Stock 13F Review: What Hedge Funds Were Buying and Selling

BioSante, Inhibitex and Idenix were among the drug stocks garnering attention from hedge funds in the third quarter.

BioSante Pharmaceuticals Announces Positive LibiGel® Pharmacokinetic Study Results

BioSante Pharmaceuticals Announces Positive LibiGel® Pharmacokinetic Study Results

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced additional results from its principal LibiGel (testosterone gel) pharmacokinetic (pK) study.

BioSante Pharmaceuticals Reports Financial Results For Third Quarter 2011 And Pipeline Update

BioSante Pharmaceuticals Reports Financial Results For Third Quarter 2011 And Pipeline Update

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced financial results for the third quarter ended September 30, 2011 and provided an update on the Company’s pipeline.

BioSante Pharmaceuticals, Inc. To Present At BioCentury And BIO Healthcare Conferences

BioSante Pharmaceuticals, Inc. To Present At BioCentury And BIO Healthcare Conferences

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M.

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review In Phase III Program

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review In Phase III Program

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer...

10 Most Shorted Stocks in Biotech

10 Most Shorted Stocks in Biotech

Short-sellers are taking aim at Savient, Avanir Pharma and other biotech firms launching new drugs in a challenging economy.

BioSante Pharmaceuticals Completes Both Pivotal LibiGel® Efficacy Trials

BioSante Pharmaceuticals Completes Both Pivotal LibiGel® Efficacy Trials

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company’s anticipated LibiGel new drug application (NDA).

BioSante Pharmaceuticals, Inc. To Present At Cancer Immunotherapy Conference

BioSante Pharmaceuticals, Inc. To Present At Cancer Immunotherapy Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 6, 2011, at the New York Academy of Medicine in New York.

Orexigen: Contrave's Odds Still Slim

Orexigen: Contrave's Odds Still Slim

Orexigen is back in business with its obesity pill but the risk and challenges ahead are still daunting and approval is far from assured.

Biotech Stock Live Chat

Biotech Stock Live Chat

TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.

BioSante Pharmaceuticals Successfully Completes LibiGel® Pharmacokinetic Study

BioSante Pharmaceuticals Successfully Completes LibiGel® Pharmacokinetic Study

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade higher from current levels.

BioSante Pharmaceuticals, Inc. To Present At Three September Healthcare Conferences

BioSante Pharmaceuticals, Inc. To Present At Three September Healthcare Conferences

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that BioSante will present at three healthcare conferences in September.

Buyers Beware

Buyers Beware

An increase in insider buying alone is not the sign of a definitive bottom.

Biosante Stock Gaps Down On Today's Open (BPAX)

Biosante Stock Gaps Down On Today's Open (BPAX)

Shares of Biosante Pharmaceuticals (Nasdaq:BPAX) were gapping down Monday morning with an open price 10.1% lower than Friday's closing price. The stock closed at $2.37 yesterday and opened today's trading at $2.13.

BioSante Pharmaceuticals Closes $48.0 Million Public Offering Of Common Stock

BioSante Pharmaceuticals Closes $48.0 Million Public Offering Of Common Stock

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the closing of its underwritten public offering of 16.

Biosante Stock Falls On Unusually High Volume (BPAX)

Biosante Stock Falls On Unusually High Volume (BPAX)

Biosante Pharmaceuticals (Nasdaq:BPAX) is trading at unusually high volume Thursday with 10.4 million shares changing hands. It is currently at four times its average daily volume and trading down 12 cents (-3.9%).

BioSante Pharmaceuticals Prices Public Offering Of Common Stock

BioSante Pharmaceuticals Prices Public Offering Of Common Stock

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the pricing of its previously announced underwritten public offering of 16.

BioSante Pharmaceuticals Announces Proposed Public Offering Of Common Stock

BioSante Pharmaceuticals Announces Proposed Public Offering Of Common Stock

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

BioSante Pharmaceuticals Reports Second Quarter 2011 Financial Results

BioSante Pharmaceuticals Reports Second Quarter 2011 Financial Results

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced its financial results for the second quarter of 2011.

BioSante Pharmaceuticals Signs Melanoma Vaccine License

BioSante Pharmaceuticals Signs Melanoma Vaccine License

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced an exclusive worldwide license of its Melanoma Vaccine to The John P.

BioSante Pharmaceuticals Announces Management Team Additions

BioSante Pharmaceuticals Announces Management Team Additions

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), today announced the appointment of Sandra Croak-Brossman, MS, Ph.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look poised to break out and trade higher from current levels.

10 Biotech Trades for Second Half of 2011

10 Biotech Trades for Second Half of 2011

These trades could represent a watershed moment in the lifeline of a biotech company.

10 Pharma Stocks Under $3

10 Pharma Stocks Under $3

Expect these to deliver strong returns, building on industry profitability and favorable company fundamentals.

BioSante Pharmaceuticals, Inc. To Present At Jefferies Global Healthcare Conference

BioSante Pharmaceuticals, Inc. To Present At Jefferies Global Healthcare Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Phillip B.

BioSante Pharmaceuticals Announces Lifting Of Clinical Hold On GVAX Prostate Cancer Vaccine

BioSante Pharmaceuticals Announces Lifting Of Clinical Hold On GVAX Prostate Cancer Vaccine

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the FDA’s clinical hold on the GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been lifted by FDA.

BioSante Pharmaceuticals Completes Enrollment In LibiGel® Phase III Safety Study

BioSante Pharmaceuticals Completes Enrollment In LibiGel® Phase III Safety Study

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study.